It has been discovered that sleeping pills lower levels of Alzheimer's proteins.

Published Date: 26 Apr 2023

Sleep issues may be a precursor to Alzheimer's disease. Many people who are eventually diagnosed with Alzheimer's have trouble falling and staying asleep years before they develop cognitive issues like memory loss.

Read Full News

Latest News

NeurologyLive® Year in Review 2025: Top Podcast Episodes Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review 2025, we've compiled the most-listened episodes this year of our biweekly podcast, Mind Moments®.

Episode 157: Clinical Advances and Unanswered Questions in Narcolepsy Marco Meglio, Lindsay McCullough, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lindsay McCullough, MD. [LISTEN TIME: 14 minutes]

From the Field: Neurologist-Written Insights From 2025 NeurologyLive® Staff

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Real-World Use of Clinical Biomarkers in the Updated Multiple Sclerosis Diagnostic Criteria Isabella Ciccone, MPH, Agne Straukiene, MD, Daniel Ontaneda, MD, PhD, Carrie Hersh, DO, MSc, FAAN

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

NeurologyLive® Year in Review 2025: Notable Trials Beginning This Year NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

Todays Updates

This Week on NeurologyLive® — December 29, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Friday 5 — December 26, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.

Assessing Antisense Oligonucleotide Apazunersen in Pediatric Angelman Syndrome: The Aspire Study Isabella Ciccone, MPH

Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.

IgA Nephropathy in 2025: Year in Review

IgA Nephropathy in 2025: Year in Review

Todays Updates

This Week on NeurologyLive® — December 29, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Friday 5 — December 26, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.

Assessing Antisense Oligonucleotide Apazunersen in Pediatric Angelman Syndrome: The Aspire Study Isabella Ciccone, MPH

Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.

IgA Nephropathy in 2025: Year in Review

IgA Nephropathy in 2025: Year in Review

Latest News

As part of NeurologyLive®'s Year in Review 2025, we've compiled the most-listened episodes this year of our biweekly podcast, Mind Moments®.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lindsay McCullough, MD. [LISTEN TIME: 14 minutes]

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

News All Time

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

FDA Expands Indication for n‐Butyl Cyanoacrylate in Chronic Subdural Hematoma Isabella Ciccone, MPH

The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.

Phase 3b STRENGTH Trial Provides Greater Support for Intrathecal SMA Gene Therapy Marco Meglio

Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.

NeuroVoices: Alireza Atri, MD, PhD, on Notable CTAD Trial Presentations, EVOKE Data Alireza Atri, MD, PhD, Isabella Ciccone, MPH

The director of the Banner Sun Health Research Institute discussed a variety of meaningful Alzheimer disease research presented at the 2024 Clinical Trials on Alzheimer's Disease Conference (CTAD).

What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers Marco Meglio

Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.

Genetic Testing in Adult Epilepsy: GEAN’s Plan to Standardize Practice and Study Adult Outcomes Marco Meglio

Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.

2024 Primary Stroke Prevention Guidelines: Key Takeaways and Clinical Implications Walter Kernan, MD, Isabella Ciccone, MPH

Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.

A Clinical Review of the 2025 Restless Leg Syndrome Guidelines Louie Pasculli, Andy Berkowski, MD, PhD

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission Marco Meglio

Sanofi's tolebrutinib fails to meet key trial endpoints for multiple sclerosis, delaying FDA review and raising questions about its future in treatment.

Understanding the Therapeutic Potential and Promising Early-Stage Data on Azetukalner for Focal Onset Seizures Marco Meglio

Christopher Kenney, MD, FAAN, chief medical officer at Xenon Pharmaceuticals, reviews encouraging long-term data behind azetukalner, a first-in-class Kv7 channel opener, as a potential treatment for focal onset seizures.

How Social Robotics and Embodied AI Could Reshape Neurology Care Neal K. Shah

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

NeurologyLive® Friday 5 — December 12, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine Isabella Ciccone, MPH

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Recommended News For You

How a California Oncologist Making $850k Spends Money

Depression risk higher among long-term breast cancer survivors than women without breast cancer history

Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco

Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News.

Year in Review: Multiple Myeloma

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer

Recommended Articles For You

Cowden Syndrome and Cancer: Understanding the Risk Factors  

The Miracle of Thyrogen Injection: A New Hope for Thyroid Cancer Treatment 

Introduction to Immune Thrombocytopenic Purpura 

Case Study: Revolutionizing PNH Treatment with Eculizumab for Superior Patient Outcomes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

2.

Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma

3.

For the treatment of vestibular schwannomas in neurofibromatosis type 2, stereotactic radiosurgery has been found to be effective.

4.

Chemoradiation Plus Immunotherapy Fails to Improve Survival in Limited-Stage SCLC

5.

Study reveals increase in late-stage breast cancer diagnoses in US

1.

Understanding Fibrosarcoma: What You Need to Know 

2.

Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More 

3.

Unraveling the Genetic Mystery of Hereditary Spherocytosis

4.

Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches

5.

The Statistical Frontier of Hematology Oncology: Diagnostics, Therapies, and Future Horizons in Hematology Oncology 2025

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Thromboprophylaxis In Medical Settings- An Update

2.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

3.

Current Scenario of Cancer- Q&A Session to Close the Gap

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot